The activity of CIKs can be redirected towards tumor targets by the combination with bispecific antibodies (BsAbs) simultaneously targeting a CIK surface antigen (e.g., CD5 or CD3) along with a tumor antigen, such as the T-cell engager CD3xCD19 blinatumomab [11,12,13,14,15,16,17]. This evidence concerns the gene CD5 and neoplasm.